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Abstract
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant endocrine tumor 
syndrome, caused by inactivating mutations of the MEN1 tumor suppressor gene at 
11q13 locus, which predisposes to develop tumors in target neuroendocrine tissues. As 
the positional cloning and identification of the causative gene in 1997, genetic diagnosis, 
by the sequencing-based research of gene mutations, has become an important 
tool in the early and differential diagnosis of the disease. Application of the genetic 
test, in MEN1 index cases and in first-degree relatives of mutated patients, has been 
constantly increasing during the last two decades, also thanks to the establishment of 
multidisciplinary referral centers and specific genetic counseling, and thanks to the wide 
availability of high throughput instruments for gene sequencing and gene mutation 
identification. The MEN1 genetic test helps the specific diagnosis of probands, and 
allows the early identification of asymptomatic carriers, strongly contributing, together 
with progressions in tumor diagnostic techniques and in pharmacological and surgical 
therapeutic approaches, to the reduction of morbidity and mortality associated with 
the syndrome. International clinical guidelines for MEN1 have been drafted by panels of 
specialists in the field, with the main goal to improve the management of the disease 
and grant patients a better quality of life. Here, we review main recommendations and 
suggestions derived by the last published general guidelines in 2012, and by most recent 
published studies about MEN1 syndrome diagnosis, clinical management, therapeutic 
approaches and patients’ quality of life.
Introduction
Multiple endocrine neoplasia type 1 (MEN1) predisposes 
to the development of multiple endocrine and non-
endocrine tumors in various organs in a single patient. 
Although the great majority of MEN1 tumors are 
generally not aggressive, and many of them present a 
long-term indolent course remaining asymptomatic 
for years (particularly non-functioning tumors; NFTs), 
malignant progression, metastatic tumors, as well as 
excessive hormone-related syndromes and derived 
complications, manifest in a significant percentage of 
patients, being responsible for a severely compromised 
quality of life (QoL) and reduction in life expectance. 
The recognition of MEN1 tumors in their early stage, 
the early-started targeted treatments for the control of 
hormone production and prevention of over-secretion-
related complications, and the surgical removal of tumors 
before their excessive growth, surrounding tissue invasion 
and metastases development are the best approaches to 
reduce negative clinical impact of MEN1. In this light, a 
delay in diagnosis negatively influences patients’ QoL and 
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survival; the necessity of early diagnosis and intervention 
is, thus, strongly felt.
Genetic test revealed as a fundamental tool for 
the early, and even pre-symptomatic, diagnosis and 
together with constant progressions in tumor diagnostic 
techniques and in pharmacological and surgical 
therapies, it has contributed in the last two decades, and 
still contributes, to the reduction of MEN1-associated 
morbidity and mortality.
Twenty years of the MEN1 gene discovery: 
from the bench to the bedside
MEN1 has been first described by Erdheim in 1903, but 
only five decades later its hereditary nature was recognized. 
The syndrome is caused by inactivating mutations of the 
tumor suppressor gene MEN1, positionally cloned in 
1997 at 11q13 locus (Chandrasekharappa et  al. 1997). 
The identification and genetic characterization of the 
causative gene, opened the possibility to the genetic 
testing and to the early and pre-symptomatic diagnosis 
of the disease. Over 1500 MEN1 loss-of-function different 
mutations (1341 germinal and 203 somatic variants) have 
been described up to September 2015 (Lemos & Thakker 
2008, Concolino et al. 2016), the great majority of them 
giving a truncated protein unable to reach the nucleus 
and exert its anti-oncogenetic functions. Approximately 
10% of patients have de novo mutations, developed at 
embryonic level, and, thus, lack of a family history.
Genetic test of MEN1 is recommended for clinical 
index cases with two or more MEN1-associated endocrine 
tumors (for the confirmation of clinical diagnosis), for 
first-degree relatives and family members of known MEN1 
mutation carriers, and also for patients with suspicious 
MEN1 phenotype (i.e. hyperparathyroidism before the 
age of 30, a multiglandular involvement, multiple and/or 
recurring pancreatic neuroendocrine tumors (pNETs) at 
any age). Asymptomatic members of a mutation-bearing 
family should undergo genetic screening as early as 
possible, better before the age of 5 years. A positive MEN1 
genetic test is indication for periodic biochemical and 
imaging screenings for MEN1-associated tumor detection, 
and for the early choice of the appropriate surgical and/or 
pharmacological treatment. Unfortunately, no correlation 
between the specific MEN1 mutation or a specific affected 
region of the gene and the MEN1 clinical phenotype 
has been described. It is not possible to foresee clinical 
manifestations based on the result of genetic test, and, 
thus, to personalize tumor prevention; all MEN1 patients 
and mutations carriers undergo the same standardized 
and periodical clinical surveillance program (Table  1), 
according to the MEN1 clinical practice guidelines (Brandi 
et al. 2001, Thakker et al. 2012).
The identification of pedigree members who do 
not bear the familial MEN1 mutation is indication for 
them to be excluded from any further investigation 
for MEN1-associated tumors (they present the same 
risk of developing the syndrome of the normal 
population) strongly contributing in reducing costs for 
unnecessary screenings.
Genetic testing consists of sequencing MEN1 
coding region (exons 2–10) and splicing sites. It allows 
to identify point mutations and small intra-exon 
deletions/insertions, but fails the identification of large 
intragenic deletions (estimated to represent up to 10% 
of MEN1 mutations) (Lemos & Thakker 2008). In case 
of a MEN1 negative sequencing test in a MEN1 family 
or in a clinically defined MEN1 patient, a gene dosage 
procedure (i.e. Southern blot analysis or multiplex 
ligation-dependent probe amplification (MLPA)), able 
to detect copy number change and gross intra-genic 
deletions, insertions or rearrangements, should be 
performed. If both sequencing and allele copy dosage 
screenings resulted negative, haplotype analysis of 
11q13 locus, with flanking microsatellite markers, 
should be considered to identify individuals bearing 
the MEN1 ‘causative’ familial haplotype, in a family 
with at least two affected individuals spanning at least 
two generations.
The presence of a phenocopy should be suspected in 
presence of a negative MEN1 genetic test, by sequencing, 
gene dosage and 11q13 haplotype analyses. Phenocopies 
are estimated to account for up to 5% of MEN1-like cases 
(Turner et  al. 2010), and their recognition, by specific 
genetic tests, is important for differential diagnosis 
and correct clinical and therapeutic management of 
patient. Principal MEN1 phenocopy is the multiple 
endocrine neoplasia type 4 (MEN4), a recently identified 
hereditary endocrine tumor syndrome causes by loss-of-
function mutations of the CDKN1B tumor suppressor 
gene encoding the p27kip1 inhibitor of the cyclin-
dependent kinase 2. Other, rarer, MEN1 phenocopies 
are due to mutations in genes encoding members of the 
cyclin-dependent kinase inhibitor (CDKN) family, such 
as CDKN1A (p21cip1), CDKN2B (p15Ink4b) or CDKN2C 
(p15Ink4c). All together mutations in these four CDKN 
genes are suspected to cover less than 2% of clinical 
MEN1 patients without a MEN1 mutation (Turner et al. 
2010); genetic screening of these genes is suggested in 
these cases, starting from CDKN1B.
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Table 1 Recommended biochemical and imaging surveillance program for MEN1-associated main tumors in MEN1 patients and 
in MEN1 mutation carriers.
 
 
Tumor (estimated frequency)
Suggested 
starting age 
(years)
 
 
Biochemical screening (frequency)
 
 
Imaging analysis (frequency)
Parathyroid adenoma (over 90%) 8  – Morning fast serum calcium and PTH 
(annually)
 – Morning fast serum ionized calciuma 
(annually)
Noneb
Anterior pituitary tumors (30–40%): 5  Head non-contrast MRI  
(every three-five years)c
PRL-secreting adenoma (prolactinoma) 
(20%)
 Morning fast serum PRL (annually)  
Somatotropin (GH)-secreting adenoma 
(somatotropinoma) (10%)
 Morning fast serum IGF-1 (annually)  
GH-PRL-secreting adenoma (5%)  Morning fast serum PRL and IGF-1 
(annually)
 
Corticotropin (ACTH)-secreting adenoma 
(corticotropinoma) (<5%)
 Cortisol and ACTH in blood samples taken 
at different times of the day (annually)
 
LH-secreting adenoma (rare)  Morning fast serum LH (annually)  
FSH-secreting adenoma (rare)  Morning fast serum FSH (annually)  
Thyrotropin (TSH)-secreting adenoma 
(rare)
 Morning fast serum TSH and thyroid 
hormones (annually)
 
Non-functioning adenomas (<5%)  None  
GEP-NETs (30–80%):  Serum chromogranin Ad (annually)  
Gastrinoma (40–55%) 20  – Morning fast serum gastrin (annually)
 – Gastric acid outpute (annually)
 – Secretin-stimulated gastrinf (annually)
 – Selective Arterial Secretagogue 
Injection (SASI)
Noneg
Insulinoma (10–30%) 5  – Fasting glucose (annually)
 – Morning fast insulin (annually)
 – Selective Arterial Secretagogue 
Injection (SASI)h
None
Glucagonoma (<3%) <10   
VIPoma (<1%) <10 Morning fast glucagon (annually) None
Non-functioning tumors and PPoma 
(20–55%)
<10 Morning fast plasma VIP (annually) None
  Serum chromogranin A and PP (annually) MRI, CT scan or EUS of the 
abdomen (annually)
Carcinoids (over 3%): 15 None (they are typically non-secretory 
tumors)i
 
Foregut/stomach (10%)   EUS of the stomach (annually)
   Gastroscopy examination 
(with biopsy) in gastric NETs 
with hypergastrinemia and 
in gastric carcinoids type II 
(every three years)
Lung/bronchi (3.4–13.3%)   Low-dose CT scan of chest for 
bronchopulmonary 
carcinoids (every one-two 
years)
Thymus (2–8.2%) 
 
 
  
 
 
  
 
 
Low-dose CT scan and MRI of 
the neck and chest for 
thymic carcinoids (every 
one-two years)j
(Continued)
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Other genes to be considered for mutation screening 
are CDC73 (also called HRPT2, a tumor suppressor gene 
encoding parafibromin), CaSR (encoding the calcium-
sensing receptor), GNA11 (encoding the G-protein 
alpha 11), AP2S1 (encoding the adaptor protein 2 
sigma 1) for the differential diagnosis of syndromic and 
familial primary hyperparathyroidism, respectively, in 
hyperparathyroid-jaw tumor (HPT-JT) syndrome and 
familial benign hypocalciuric hypercalcemias (FHH1, 
FHH2 and FHH3), and AIP a tumor suppressor located 
on 11q13 (encoding the aryl hydrocarbon receptor-
interacting protein) associated with familial isolated 
pituitary adenomas. CDC73, CaSR, GNA11 and AP2S1 
screening is recommended in MEN1-negative individuals 
with primary hyperparathyroidism and a familial 
history of the disease. AIP mutation testing is suggested 
in all children and adolescents with prolactinoma or 
somatotropinoma.
The suggested approach for genetic screening, and 
related diagnostic surveillance, in MEN1 is schematized 
in Fig. 1.
The future of genetic diagnosis will be the application 
of high throughput next-generation sequencing (NGS), 
that allows the enlargement of nucleotide sequencing 
from single gene to multi-gene-disease-targeted panels and 
up to the entire genome, using platforms and instruments 
capable of producing hundreds of gigabytes of genetic 
data in a single run, and to include also the non-coding 
and regulatory regions of genes, that are, at the moment, 
usually excluded in Sanger’s sequencing analysis. In 
particular, NGS-targeted multi-gene sequencing, using a 
platform including an endocrine inherited tumor-related 
selected panel of genes, will be useful for the differential 
and early diagnosis of MEN1 and other inherited endocrine 
syndromes. Time and cost for performing NGS screening 
are progressively decreasing, granting, in a near future, 
 
 
Tumor (estimated frequency)
Suggested 
starting age 
(years)
 
 
Biochemical screening (frequency)
 
 
Imaging analysis (frequency)
Adrenal lesions (40%): <10 Plasma renin, aldosterone, low-dose 
dexamethasone suppression test, urinary 
cathecolamines and/or metanephrynesk
Abdominal imaging by MRI or 
CT scan (annually with 
pancreatic imaging)
Adrenal cortical tumors (40%)    
Pheocromocytoma (<1%)    
aInonized calcium should be checked if calcium results to be normal or to be intermittently high in presence of a PTH higher than normal 
reference range.
bNeck ultrasound and Tc99 scintigraphy (sestamibi) are suggested for pre-operatory neck exploration before parathyroidectomy (usually in patients with 
hypercalcemia and hypercalciuria) for the localization of enlarged, extra-numerary and/or ectopic parathyroid glands.
cHead MRI is usually the imaging technique of choice for the detection of pituitary adenoma since it is more detailed than CT scan and it identifies 
pituitary macroadenomas and most of microadenomas. MRI might not detect microadenomas smaller than 3 mm. sensitivity and specificity for secreting 
pituitary tumors is approximately 90%, diagnostic accuracy in detecting non-functioning microadenoma is less established.
dSerum concentration of chromogranin A is still the most valuable marker of GEP-NETs; its concentration is elevated in about 100% of gastrinomas, 80% 
of neuroendocrine tumors of the small intestine and 69% of non-functioning pancreatic neuroendocrine tumors. However, sensitivity of this dosage for 
non-functioning tumors is relatively low (33–58%).
eGastric acid output is measured if gastrin level is high. The occurrence of both high fasting serum gastrin concentration and increased basal gastric acid 
secretion (gastric pH <2) is indication of a gastrinoma.
fSecretin-stimulated gastrin is measured if both gastrin level and gastric acid output are high.
gGastrinoma imaging is suggested after a biochemical diagnosis, only to localize tumors before surgery intervention. Due to the small size (<0.5–1 cm) of 
duodenal and pancreatic gastrinomas in MEN1, mostly of them are usually missed by somatostatin receptor scintigraphy or other conventional imaging. 
Multi-slice CT scan is the highest sensibility technique able to acquire an entire anatomic region without gaps. EUS can be used for pancreatic 
gastrinomas, but it fails in recognize small adenoma in the duodenum. Intraoperative EUS of the duodenum and of the pancreas has a higher sensitivity 
than pre-operative imaging. Somatostatin receptor scintigraphy is highly recommended for lymph node and liver metastases.
hSASI test, performed using secretin as a secretagogue, locates gastrinomas by determines the arteries feeding the tumor. It has been shown to have a 
high predictive value in the Japanese experience, but similar accuracy was not reproduced in other studies (Tonelli et al. 2012).
iBiochemical dosages of urinary 5-hydroxyindolacetic acid and of serum chromogranin A are not helpful for carcinoid diagnosis.
jCT scan demonstrated a 95% sensitivity for detecting thymic carcinoids and it is superior to chest MRI in detecting intrathoracic lesions.
kThese biochemical investigations are recommended only for patients with signs and symptoms of functioning adrenal tumors and/or with an identified 
tumor larger than 1 cm.
ACTH, Adrenocorticotropic hormone (corticotropin); CT, Computed tomography; EUS, Endoscopic ultrasounds; FSH, Follicle-stimulating hormone; 
GEP-NETs, Gastro-entero-pancreatic neuroendocrine tumors; GH, Growth hormone; IGF-1, Insulin-like growth factor-1; LH, Luteinizing hormone; MRI, 
Magnetic resonance imaging; PP, Pancreatic polypeptide; PTH, Parathyroid hormone; PRL, Prolactin; TSH, Thyroid stimulating hormone; VIP, Vasoactive 
intestinal peptide.
Table 1 Continued.
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the possibility of a more and more capillary application 
of this technique.
Clinical practice guidelines for MEN1: 
recommendations and suggestions. 
An evolving story 
The first consensus statement, edited by an international 
panel of specialists in the area of MEN syndromes, was 
published in 2001 on both MEN1 and MEN2, according to 
data deriving from the Seventh International Workshop 
on Multiple Endocrine Neoplasias (Brandi et  al. 2001). 
These clinical guidelines have been updated, for MEN1, 
in 2012 (Thakker et al. 2012), after a systematic review of 
literature and according to novel findings about the clinic 
aspects and genetic bases of MEN1 syndrome, the constant 
improvement of diagnostic tools, the published surgical 
practice for MEN1 tumors and the availability of new drugs 
for the control of hormone over-production-associated 
manifestations of the disease. Guidelines include a 
complete and detailed list of recommendations and 
suggestions for the diagnosis, treatment and management 
of the syndrome.
Prior to 1980, approximately 80% of deaths were 
caused by pNETs, mostly due to gastrinoma-derived 
gastric acid hypersecretion that causes multiple 
duodenal ulcers and severe gastro-intestinal bleeding and 
perforation. Improvements in pharmacological therapy, 
controlling the excessive gastric acid secretion and the 
hormone excess-derived syndrome, have strongly reduced 
mortality related to these complications. Nevertheless, 
despite the advances in treatment of MEN1 tumors and 
associated functional syndromes, the life expectancy 
of patients remains shorter than normal population 
(death mean age: 55 years) (Norton et al. 2015a). MEN1 
probands present a mean interval of survival of 18 years 
after the clinical diagnosis. Causes of death have changed 
in the last decades, and they are now prevalently due to 
Figure 1
Schematic representation of suggested approach for MEN1 syndrome genetic testing in a clinical setting. Genetic screening is indicated to: (1) confirm 
clinical diagnosis in index cases, (2) identify asymptomatic carriers among first-degree relatives of a mutated subject, (3) identify non-mutated family 
members. A MEN1 index case (*) is considered: (1) a patient meeting clinical criteria for MEN1 (i.e. two or more MEN1-associated tumors, or one 
MEN1-associated tumor and a first-degree relative with MEN1), (2) a suspicious MEN1 patient (i.e. multiple parathyroid adenoma before the age of 40, 
recurrent primary hyperparathyroidism (PHPT) after surgery, gastrinoma and/or multiple pancreatic neuroendocrine tumors (pNETs) at any age), (3) an 
atypical MEN1 phenotype (i.e. development of one main MEN1-associated tumor and of one non-classical and/or rare MEN1 tumor, such as parathyroid 
adenoma in association with adrenal gland tumor).
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the malignant progression of neuroendocrine tumors 
(NETs), mostly pNETs and thymic carcinoids, which 
are responsible for 40–50% and 12–24% deaths, 
respectively. Moreover, the increased life expectance 
in MEN1 patients has increased, at the same time, 
morbidity and mortality due to the development of other 
syndrome-related tumors, such as adrenal tumors, gastric 
and bronchopulmonary carcinoids, neurofibromas, 
meningioma, ependymoma, breast cancer, which 
manifest with a higher frequency in MEN1 patients 
with respect to normal population (Ito & Jensen 2016). 
Therefore, further enhancements of techniques and 
methods for the earliest identification of MEN1-related 
tumors at their early stage, as well as the development 
of tailored, specific, effective and safe therapies are still 
required. Currently, recognition, localization, staging and 
follow-up of MEN1 NETs are performed by tumor marker 
measurements in serum and urine, and by imaging, such 
as computed tomography (CT) scan of chest, abdomen 
and pelvis, magnetic resonance imaging (MRI) of chest, 
abdomen and liver, endoscopic ultrasounds (EUS) of 
stomach and abdomen, contrast-enhanced abdominal CT 
and non-contrast MRI of the head. The rationale for an 
aggressive surveillance approach in MEN1 patients and 
asymptomatic carriers is based on the presumption that 
the early pre-symptomatic detection of MEN1 neoplasias 
may reduce the associated mortality (Thakker et al. 2012), 
but, at the moment, there are no clear data to support the 
notion that more frequent and numerous biochemical 
and imaging examinations can lead to improved 
survival outcomes in MEN1. Moreover, the ratio between 
diagnostic benefits of imaging and risks due to periodical 
exposure to ionizing radiation should be taken into 
account. Indeed, recent data have demonstrated to 3-fold 
increase in the per capita individual radiation exposure 
from medical diagnostic radiation sources over the past 
25 years (Casey et al. 2017), and it has been estimated that 
exposure to ionizing radiation for diagnostic purposes 
may account for 2% of all tumors (Flasar & Patil 2014). 
This oncogenic relative risk could also be higher in 
patients with a genetic tumor-predisposing syndrome, 
bearing a mutation in genes involved in DNA repair 
or tumor suppression, such as MEN1, who constantly 
undergo repeated exposure to diagnostic doses of 
ionizing radiation (Allan 2008). Very recently, Casey 
and coworkers (Casey et  al. 2017), retrospectively 
investigated, for the first time, the effective dose (ED) 
of ionizing radiation received by a cohort of 43 MEN1 
patients to evaluate if the cumulative radiation exposure 
in surveillance program increases the oncogenic risk. 
Authors failed in finding an association between the 
high mean ED in their cohort and the secondary tumor 
induction, but that could be due to the relatively 
short period of the retrospective study (only 8  years). 
Prospective studies, with longer follow-up are required 
to establish the real risk of secondary tumors caused 
by repeated radiation exposure in MEN1 patients; the 
optimal imaging surveillance protocol in MEN1 remains 
to be defined.
Etchebehere and coworkers compare NET lesion 
detectability among somatostatin receptor scintigraphy 
(SRS) with 99mTc-hydrazino nicotinamide (HYNIC)-
octreotide SPECT/CT, 68Ga-DOTATATE PET/CT and whole-
body diffusion-weighted (WB DWI) MRI (Etchebehere et al. 
2014). 68Ga-DOTATATE PET/CT seems to be more sensitive 
for detecting well-differentiated NET lesions, pulmonary 
lesions and metastases in lymph nodes (Schraml et  al. 
2013) and for the staging of NETs. WB DWI MRI revealed as 
an efficient new method with high accuracy and without 
ionizing radiation exposure, showing a comparable overall 
primary lesion detection rate to 68Ga-DOTATATE PET/CT, 
but superior in detecting liver and bone metastases. SSRS 
SPECT/CT should be used only when 68Ga-DOTATATE 
PET/CT and WB DWI MRI are not available.
Unfortunately, to date, there is a lack of controlled 
clinical trials to evaluate the efficacy of diagnostic 
techniques and approaches in MEN1 and the effectiveness 
of surgical and/or pharmacological interventions for 
tumors associated with this syndrome. Many diagnostic 
recommendations, as well as data about surgery and drugs, 
are derived from long-term experiences of specialists in 
the area, from clinical work of numerous specialist referral 
centers worldwide, and from trials performed on sporadic 
counterparts of MEN1-associated tumors.
Quality of life in patients with MEN1
The diagnosis of a tumor is a shock and a great challenge 
for patients and their families. This is followed by lack 
of patient’s personal control over the current treatment 
method and uncertainty of its outcome. Feelings of 
depression, anxiety and fear are very common and 
are normal responses to this life-changing experience. 
Physical symptoms such as pain, nausea or extreme 
tiredness (fatigue) can also manifest. All these 
considerations are even more true after a diagnosis of 
MEN1 by which a patient becomes aware of the certainty 
of develop multiple and often recurrent tumors during his 
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life. Some studies investigated psychological and physical 
responses after a diagnosis of cancer, but only one has 
been specifically conducted about the QoL of MEN1 
individuals and psychosocial consequences of the disease 
diagnosis. Berglund and coworkers analyzed health related 
QoL (HRQoL) in 29 Swedish MEN1 patients through the 
administration of four questionnaires (Hospital Anxiety 
and Depression Scale (HADS), Impact of Event Scale (IES), 
Life Orientation Test (LOT) and Short Form-36 (SF-36)), 
first at one in-hospital stay and then at home 6 months 
later (Berglund et al. 2003). On the basis of medical record 
data, patients were divided into three levels of disease 
severity, named as 0, 1 and 2. The ‘0’ level means that 
the MEN1 diagnosis has not been verified and no surgery 
or medical treatment have been yet initiated. The ‘1’ 
level corresponds to a verified MEN1 diagnosis with a 
limited disease, associated with one or more performed 
surgeries. The ‘2’ level is a verified MEN1 diagnosis with 
an extensive disease, for which several surgeries have been 
already performed and pharmacological treatments have 
been administered. SF-36 scores resulted lower for general 
health and social functioning with respect to normal 
population. Approximately 70% of MEN1 patients were 
defined as pessimists about their uncertain future with the 
fear of what might happen to themselves, their children 
and other relatives. This pessimism may also concern 
the uncertainty regarding the progression of the disease 
and how this might impact negatively upon their daily 
activities, and their ability to maintain their present work 
situation. Authors evidenced that patients presenting 
higher burden disease and undergoing extensive 
treatments may need some support for their psychosocial 
distress, after discharge from hosital.
Later on in 2007, Strømsvik and coworkers (Strømsvik 
et al. 2007) conducted a qualitative study on 29 Swedish 
patients with MEN1 exploring how they live with the 
disease. Patients have been encouraged to report any 
psychological, physical and social limitations in their 
daily activity and in their job life and to judge how 
these limitations influence their general QoL. The study 
showed that most participants tried to adjust their novel 
situation by changing lifestyle and focusing on nutrition 
and physical activity. They reported a shift in priorities 
after developing MEN1 or learning about their personal 
risk. Changing values help the patients managing the 
situation. Surprisingly, a majority of them described 
themselves as being healthy, despite disease severity, 
surgery, pharmacological treatments and other physical 
and psychological symptoms. Participants reported that 
interpersonal relationships with family and friends were 
one of the most valuable aspects in their lives. Moreover, 
the majority of participants indicated overall satisfaction 
with being in a clinical surveillance and follow-up 
program, under the supervision of specialist health care 
providers, since this grants to start therapy immediately 
at the time of tumors development, with a higher 
possibility to be positively cured. Regarding job situations 
and environments, result of tests evidenced a patient’s 
sense of control by going on, normally, with their job 
lives, and only a soft sense of fear about disease-related 
professional limitations.
Various non-disease-specific QoL tests have been 
evaluated in sporadic NETs, but, to date, no conclusive 
data have been published. Although there are evidences 
suggesting a correlation between disease symptoms and 
tumor burden with QoL, further perspective trials are 
warranted to understand the impact of disease diagnosis 
and progression on physical and psychological QoL of 
patients and families (Chau et  al. 2013). Unfortunately, 
no specific questionnaires measuring HRQoL in MEN1 
or other hereditary tumors have been developed yet, 
and generic questionnaires may overlook some general 
aspects but skip more specific tracts of the disease. 
Targeted perspective trials in MEN1 individuals are surely 
required to design optimal HRQoL evaluation tests for this 
syndrome. Indeed, an increased knowledge about MEN1, 
not only about genetic and clinical features but also 
on the psychosocial aspects of the disease, may help to 
provide patients with optimal care, psychological support 
and a better QoL for them and their families.
Parathyroid adenomas
Primary hyperparathyroidism (PHPT), due to parathyroid 
hyperplasia and/or adenoma, is the most common 
(approximately 90% of cases by the age of 40 and 
nearly 100% by 50) and, usually, the first endocrine 
manifestation in MEN1, with a common age of onset 
in the early third decade of life (20–25  years). PHPT in 
MEN1 can present a long-term asymptomatic course 
and it is usually recognized by the incidental finding 
of elevated serum level parathyroid hormone (PTH) in 
association with hypercalcemia or, in some cases, with 
normocalcemia. Diagnostic screening includes annual 
dosage of intact serum PTH and calcemia (Table  1). 
Patients with hypercalcemia should undergo continuous 
surveillance, including annual calciuria, imaging of 
the urinary tract (to prevent nephrolithiasis) and bone 
T234Thematic Review F Marini et al. Diagnostic and therapeutic 
management of MEN1
En
d
o
cr
in
e-
R
el
at
ed
 C
an
ce
r
24:10
DOI: 10.1530/ERC-17-0203
http://erc.endocrinology-journals.org © 2017 Society for Endocrinology
Printed in Great Britain
Published by Bioscientifica Ltd.
mineral density (BMD) evaluation by dual-energy X-ray 
absorptiometry (DXA). MEN1 patients generally develop 
multiple poly-glandular parathyroid adenomas, and 
usually all four parathyroids are affected during lifetime. 
The great majority of parathyroid tumors show loss 
of heterozygosity (LOH) at 11q13, suggesting that the 
complete loss of wild type menin in parathyroid cells is a 
fundamental step for adenoma development. Tumors are 
different in time of development and size, and each one 
has to be considered as an independent clonal adenoma, 
as confirmed by the different pattern of 11q13 LOH found 
in any single tumor, even from the same patient (Dwight 
et  al. 2002). MEN1 LOH in multiple glands, within the 
same individual, is ultimately caused by independent 
genetic changes that arise randomly in any single gland 
and that are presumably driven by still unknown genetic, 
epigenetic, physiological and/or environmental factors. 
An early gland hyperplastic phase has been suggested, 
by not certainly proven. Recently, it has been suggested 
that MEN1 parathyroid tumorigenesis could be under the 
control of a ‘negative feedback loop’ between miR-24-1 
and menin, which mimics the second hit of Knudson's 
hypothesis, silencing the expression of the second 
wild type copy of MEN1 in a post-transcriptional, still 
reversible, epigenetic manner, before the irreversible 
genetic deletion/inactivation of the second wild type 
allele (Luzi et  al. 2012). This LOH-based mechanism of 
single gland independent tumorigenesis causes a non-
synchronous enlargement of parathyroids at the time of 
neck exploration and surgery, and it is considered to be 
responsible for the high rate of tumor recurrences after 
partial and subtotal parathyroidectomy.
Surgery is the treatment of choice for the control of 
hypercalcemia. Timing of surgery has not clearly defined 
yet and it should be decided based on single patient clinical 
characteristics. Parathyroidectomy is usually performed in 
patients with notable hypercalcemia in association with 
hypercalciuria to prevent and/or reduce the associated 
clinical consequences of high calcium levels, such as severe 
reduction of BMD, nephrolithiasis, gastric hypersecretion, 
mental disturbs, vomiting, abdominal and bone pain, etc. 
Surgery to correct PHPT and hypercalcemia is fundamental 
in MEN1 patients with Zollinger–Ellison syndrome (ZES), 
since the restoring of normal calcium level contributes 
to reduce gastric acid output, ameliorating the clinical 
findings of ZES and reducing the risk of peptic ulcers. Type 
of operation for parathyroid surgery in MEN1 patients 
is still controversial: Some authors suggest minimal 
invasive surgery with ablation of only the enlarged 
glands, others suggest subtotal removal of 3.5 glands, and 
some others total parathyroidectomy with heterotopic 
auto-transplantation of fresh or cryopreserved normal 
parathyroid tissue into the brachioradialis muscle of the 
non-dominant forearm (Norton et al. 2015b). Partial and 
subtotal parathyroidectomy have both high probability 
of recurrences (i.e 40–60% within 10–12  years after 
surgery), and patients have to be annually monitored 
for this possibility; conversely, re-inplant after total 
parathyroidectomy presents a high incidence of graft 
failure and subsequent permanent hypoparathyroidism. 
Considering the presence of an after-surgery PHPT-
free period, some surgeons have suggested to surgically 
remove only parathyroid gland/glands that appear to be 
enlarged and adenomatous (that presumably have already 
lost both wild type copies of MEN1), and do not touch 
parathyroids appearing normal in volume (presumably 
still retaining the second wild type copy of the gene and 
still being normally functioning), to delay, mostly for 
young patients, the surgical-derived hypoparathyroidism. 
Indeed, post-surgical permanent hypoparathyroidism is 
an irreversible complication of total parathyroidectomy, 
which is more difficult to be treated and controlled 
than PHPT and is responsible for a great reduction of 
the general QoL. In this light, the choice of parathyroid 
surgery approach has to be defined based on every single 
patient personal and clinical features; it should primarily 
take into account three main goals: (i) to restore normal 
calcium level (reducing and/or preventing secondary 
damages due to long-term elevated serum calcium 
concentration) and maintain normocalcemia, for as long 
as possible before recurrence occurs; (ii) to avoid or to 
delay, for as long as possible, permanent post-surgical 
hypoparathyroidism; and (iii) to facilitate any possible 
future surgery for recurrences.
Intraoperative dosage of PTH is suggested to 
monitor the correct ablation of all adenomatous 
and/or hyperplastic parathyroids (Nilubol et  al. 2013); 
measurement has to be performed 5–10  min after the 
removal of the last abnormal gland, and a decreasing of at 
least 50% of intact serum PTH (with respect to basal level 
before surgery) is indicative of a correct ablation of all 
pathological parathyroid tissue (with a clinical sensibility 
of about 87% after 5 min and approximately 95% after 
10 min). Transcervical thymectomy is recommended at 
the time of neck surgery, especially in men and patients 
with a family history of thymic carcinoids.
Some MEN1 patients require re-operation to cure 
recurrent and/or persistent PHPT; a novel neck intervention 
is often difficult, can create definitive and/or recurrent 
tissue injuries (i.e laryngeal nerve) and it is associated to 
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increased morbidity. Moreover, in some cases re-operation 
can be not indicated due to the clinical and emotional 
condition of patients, or patients could refuse to undergone 
a second intervention. Recently, a retrospective study 
evaluated safety and efficacy of multiple percutaneous 
parathyroid ethanol ablation (PEA) treatment (average 
of 2.2 real-time sonographic-guided intra-parathyroid 
ethanol injections per patient) in 37 MEN1 patients with 
recurrent PHPT, demonstrating this technique as able to 
safely and effectively control hyperparathyroidism with a 
low rate of hypocalcemia and permanent complications, 
when performed by an experienced radiologist (Singh 
Ospina et al. 2015). However, PEA cannot replace primary 
parathyroid surgery, but it might represent a possible 
viable and safer alternative to re-operation, to control 
recurrent PHPT when a second intervention is not 
indicated. Moreover, PEA is not a definitive therapy, as 
demonstrated by the short duration of normal calcium 
level after the procedure, and it requires to be repeated 
when hypercalcemia recurs.
PHPT can also be pharmacologically controlled by 
calcimimetics (i.e. cinacalcet), a class of calcium-sensing 
receptor agonists that demonstrated to reduce PTH release 
by parathyroid cells and, at the same time, to control 
cell growth. Cinacalcet normalizes serum calcium in 
70–80% of patients with PHPT. This effect is maintained 
over 5  years. Serum calcium increases back to baseline 
levels when the treatment is stopped. This drug neither 
impacts BMD value nor lowers biochemical markers 
of bone turnover. There are no documented effects on 
hypercalcemic symptoms, renal stones or QoL (Khan 
et al. 2017). A study conducted on the patients with end-
stage renal disease (ESRD) and related PHPT showed that 
parathyroidectomy improved QoL, whereas cinacalcet did 
not (van der Plas et  al. 2017). For these reasons, today, 
cinacalcet is not recommended as a first-line treatment 
choice for the general management of PHPT, but it is 
suggested as an alternative to parathyroid surgery in 
patients not meeting the criteria for parathyroidectomy, 
for those who failed a previous intervention, or for those 
presenting recurrence who refuse to undergo any further 
surgical interventions. This drug has demonstrated to be 
well tolerated and safe in MEN1 patients, and to be able 
to restore normal calcium homeostasis (Moyes et al. 2010, 
Giusti et al. 2016).
Anterior pituitary tumors
Anterior pituitary tumors in MEN1 have a variable 
incidence from 15 to 50% in different series, with a 
mean age of onset in the fourth decade of life, and 
early cases described by the age of 5 years. Even though 
pituitary tumors are relatively benign, they can cause 
significant morbidity due to hormone hypersecretion, 
hypopituitarism and compression of adjacent structures 
(principally optic chiasm with subsequent severe 
headaches and visual field defects). Clinical manifestations 
are similar to sporadic pituitary adenomas and depend 
on secreted hormone/hormones and size of tumors. 
Approximately 60% of these tumors secrete prolactin 
(PRL), 25% secrete growth hormone (GH), 5% secrete 
adrenocorticotropic hormone (ACTH) and the remaining 
presumably being NFTs. MEN1 pituitary adenomas tend 
to be larger in size than sporadic counterparts (84% vs 
24%), to present a more aggressive behavior and to have a 
reduced response to pharmacological therapy (particularly 
prolactinoma; 56% vs 10%), necessitating an early 
surgery (Vergès et al. 2002). In this light, early diagnosis, 
by genetic test in carrier’s relatives, is fundamental 
to prevent tumor growth and to control, as soon as 
possible, hormone release. Indeed, in MEN1 children and 
adolescents, conversely to adults, pituitary tumors are 
the second most frequent manifestation of the disease 
maybe because they, even if still asymptomatic, are earlier 
diagnosed thanks to the periodic diagnostic program 
immediately started at the time of genetic diagnosis. This 
early identification of pituitary tumors and the subsequent 
early-started specific therapy help in the reduction of 
damages due to the prolonged exposition to excessive 
pituitary hormones and/or in preventing tumor growth 
and derived compression of pituitary-adjacent structures. 
However, no genotype-phenotype correlation is observed 
and all mutation carriers have to be periodically screened 
for all MEN1 pituitary tumor types, according to the 
same screening protocol (Table  1). Life-long diagnostic 
follow-up is indicated because tumors may recur after 
surgery. Current guideline suggested screenings consist 
of annual measurement of plasma PRL and insulin-like 
growth factor-1 (IGF-1), and head MRI every 3–5  years 
(Thakker et al. 2012) (Table 1). However, recently Livshits 
and coworkers suggested that annual dosage of PRL alone 
could be not sufficient to early detect pituitary adenoma, 
and that MRI scan should be performed at a more 
frequent interval than 3–5  years (Livshits et  al. 2016). 
Indeed, the finding of an elevated PRL, in association with 
a negative MRI scan, could, falsely, suggest the presence 
of a small microprolactinoma (undetectable by imaging 
scan), but it could be really due to a non-functioning 
pituitary tumor causing intrasellar compression (even in 
case of small microadenomas) or compression of pituitary 
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stalk, both responsible for increase in PRL level even in 
absence of a PRL-secreting tumor (Arafah et  al. 2000). 
These non-functioning adenomas are not detected by 
annual biochemical analysis but they can grow rapidly 
compressing and damaging adjacent structures. Authors 
suggested that the head MRI scan should be performed 
every 1–2 years in all MEN1 patients (Livshits et al. 2016).
Therapy of pituitary adenomas in MEN1 is the 
same of sporadic tumors. The first-line therapy for 
prolactinomas is principally based on pharmacological 
control of PRL over-secretion with dopamine agonists 
(bromocriptine and cabergoline); trans-sphenoidal 
surgery and radiotherapy are usually reserved for drug-
resistant tumors, whose growth and hormone release 
cannot be controlled by pharmacological therapy, and 
for macroadenomas compressing adjacent structures 
and generating neuro-ophthalmological compliances. 
Conversely, for GH-secreting tumors the approach of 
choice is trans-sphenoidal surgery; administration of 
somatostatin analogs (SSAs; octreotide or lanreotide) for 
the control of GH over-secretion is reserved for second 
line therapy or for patients not eligible for surgery.
Gastro-entero-pancreatic neuroendocrine 
tumors (GEP-NETs)
GEP-NETs clinically affect 30–80% of MEN1 patients, 
and 80–100% in postmortem studies. They are typically 
multiple tumors, arising as single independent event 
following the LOH at 11q13. The appearance is often as 
diffuse microadenomatosis (multiple tumors > 0.5 cm) of 
the pancreas and the duodenum; a small percentage of 
MEN1 patients (less than 13%) develop macro-tumors 
(>2 cm), mostly of them being non-secreting tumors. 
GEP-NETs are classified in functioning GEP-NETs and NFTs. 
Functioning GEP-NETs includes gastrin-secreting tumors 
(gastrinomas; approximately 50% of MEN1 patients), 
insulin-secreting tumors (insulinomas; 10–30% of MEN1 
patients), glucagon-secreting tumors (glucagonoma; 
less than 3% of MEN1 patients), vasoactive intestinal 
peptide (VIP)-secreting tumors (VIPoma; less than 1% of 
MEN1 patients). Functioning tumors may result in the 
associated clinical syndrome of hormone excess. NFTs 
do no secrete hormone or may release some hormonally-
inactive peptides, such as pancreatic polypeptide (PP), 
chromogranin A, neurotensin, neuron-specific enolase 
or ghrelin.
Gastrinoma is the most frequent functioning GEP-NET 
in MEN1 (approximately 40–55% of patients). Conversely 
to the sporadic counterpart, MEN1 gastrinomas occur 
principally in the duodenum (more than 80% of cases) 
and manifest as multiple microadenomas (<0.5 cm), are 
diagnosed by the age of 40 years, and present lymph node 
metastases at the time of diagnosis in 34–85% of cases 
(Yates et al. 2015). Diagnosis of gastrinoma is made with 
a fasting gastrin 10 times over the gastrin normal upper 
limit of 100 pg/mL, in presence of hyperchloryhydria or 
pH < 2. If fasting gastrin levels are below the diagnostic 
level of 1000 pg/mL, gastrin stimulation test by 
12 h-fasting intravenous injection of secretin is useful 
in establishing the diagnosis of gastrinoma (gastrin is 
dosed a baseline, then an intravenous bolus of 2–3 U of 
secretin per kilogram of body weight is administered 
over 30 s and serum gastrin levels are then measured at 
2.5, 5, 7.5, 10, 15 and 30 min after infusion). A gastrin 
increase of 120–500 pg/mL with respect to baseline value 
and a gastrin rise of 110 pg/mL immediately after secretin 
infusion strongly suggest gastrinoma; approximately 90% 
of patients with gastrinoma have a positive secretin test. 
Imaging screening is suggested after the biochemical 
diagnosis to localize tumors. Majority of MEN1 gastrinomas 
are multiple tumors localized in the submucosa of the 
proximal duodenum. Given their specific localization, 
their commonly reduced size (less than 0.5 cm) and their 
multiplicity, majority of MEN1 gastrinomas are often 
missed by SRS or conventional imaging surveillance (CT 
scan, MRI and EUS). Thin-section multi-slice CT scan 
of the abdomen demonstrated, also in our long-term 
experience with MEN1 patients, a very good accuracy in 
the localization of duodenal gastrinomas, and it should be 
the initial imaging method for these tumors (Pfannenberg 
et al. 2005). Pancreatic gastrinomas are usually investigated 
by CT, MRI and/or EUS (Table  2) (Yates et  al. 2015). 
Gastrinoma is often associated to hypergastrinemia and 
multiple peptic ulcers of the duodenum (ZES). Symptoms 
of ZES can be improved by restoring normocalcemia in 
MEN1 patients with concurrent PHPT, in up to 20% of 
cases. Indeed, PHPT and hypercalcemia both increase 
gastrin secretion and reduce the gastric acid anti-
secretory effects of drugs. Therefore, the normalization 
of calcium and PTH level is recommended before 
starting pharmacological therapy both to ensure the real 
effectiveness of the treatment and the establishment of 
the correct dosage. Medical therapy is aimed to reduce 
gastric acid over-secretion. It consists principally of 
histamine-2 receptor antagonists (cimetidine, ranitidine, 
famotidine), proton pump inhibitors (PPIs; omeprazole, 
lansoprazole, pantoprazole) and SSAs (octreotide and 
lanreotide). These drugs have demonstrated a long-term 
effectiveness and safety in controlling hypergastrinemia 
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Table 2 Main characteristics of imaging techniques for detection of gastro-entero-pancreatic neuroendocrine tumors 
(GEP-NETs).
Tumor type Imaging technique Advantages Limitations
Pancreatic 
gastrinoma
CT scan  – High sensitivity and specificity
 – Able to detect small lesions down to 0–3 cm
 – Assessment of metastatic disease
 – Exposure to ionizing radiations
 MRI  – High sensitivity and specificity
 – Better soft tissue contrast than CT
 – No ionizing radiations
 – Long examination time
 – High cost
 – May miss pNETs less than 1.5–2 cm
 EUS  – The most sensitive modality to detect intra-
pancreatic tumors
 – Allows for tissue biopsy and offer the 
possibility of lesion tattooing
 – Detection of lymph node metastases
 – No ionizing radiations
 – Invasive technique, the procedure 
requires use of conscious sedation
 – Operator-dependent
 – Low sensitivity for distal pancreas
 SRS with In-DPTA-
octreotide 
(octreoscan)
 – High sensitivity (overall 78%). More sensitive 
than cross-sectional imaging (MRI, CT) 
 – Allows a whole-body imaging at one time
 – Detection of distant metastases (bone, distant 
lymph nodes, soft tissues)
 – Missing the 35–50% of pNETs less than 
1 cm
 68Ga-DOTATATE-
PET/CT 
 – Greater sensitivity (92–94%) (down to 2–5 mm)
 – Excellent specificity (85%)
 – Allows a whole-body imaging at one time
 – Shorter imaging time
 – Lower radiation exposure
 – Cheaper cost
 – Gives a panoramic view of MEN1-related 
lesions (not only pNETs) at one assessment 
with a good sensitivity/specificity (including 
pituitary adenomas (75/83%) and adrenal 
adenomas (75/83%))
 – Beneficial for imaging of pNET metastases 
(liver and bone, distant lymph nodes, soft 
tissues)
 – Exposure to ionizing radiations
 – Vantages and positive data on its 
application are mostly derived from 
sporadic pNETs
 – A recent study on 33 MEN1 patients 
reported a low lesion detection rate for 
small tumors (<1 cm) (Albers et al. 2017)
 – The high physiological uptake of 
radiolabeled DOTATATE by the 
posterior portion of the pancreatic 
head can mask the real tumor uptake 
and can be responsible for the low 
detection rate of primary tumors in this 
region of the pancreas
Duodenal 
gastrinoma
Multi-slice CT scan  – High sensitivity and specificity
 – Able to detect small lesions down to 0–3 cm
 – Able to detect multiple lesions in the 
submucosa of the duodenum
 – Assessment of metastatic disease
 – Exposure to ionizing radiations
 EUS  – Allows for tissue biopsy and offer the 
possibility of lesion tattooing
 – Detection of lymph node metastases
 – No ionizing radiations
 – Invasive technique, the procedure 
requires use of conscious sedation
 – Operator-dependent
 – Low sensitivity for distal pancreas
 SRS with In-DPTA-
octreotide 
(octreoscan)
 – High sensitivity (overall 78%). More sensitive 
than cross-sectional imaging (MRI, CT) 
 – Allows a whole-body imaging at one time
 – Detection of distant metastases (bone, distant 
lymph nodes, soft tissues)
 – Missing the 35–50% of pNETs less than 
1 cm
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 – Greater sensitivity (92–94%) (down to 2–5 mm)
 – Excellent specificity (85%)
 – Allows a whole-body imaging at one time
 – Shorter imaging time
 – Lower radiation exposure
 – Cheaper cost
 – Gives a panoramic view of MEN1-related 
lesions (not only pNETs) at one assessment 
with a good sensitivity/specificity (including 
pituitary adenomas (75/83%) and adrenal 
adenomas (75/83%))
 – Beneficial for imaging of pNET metastases 
(liver and bone, distant lymph nodes, soft 
tissues)
 – Exposure to ionizing radiations
 – Vantages and positive data on its 
application are mostly derived from 
sporadic pNETs
 – A recent study on 33 MEN1 patients 
reported a low lesion detection rate for 
small tumors (<1 cm) (Albers et al. 2017)
 – The high physiological uptake of 
radiolabeled DOTATATE by the 
posterior portion of the pancreatic 
head can mask the real tumor uptake 
and can be responsible for the low 
detection rate of primary tumors in this 
region of the pancreas
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and ZES complications (Wolin 2012, Plöckinger 2012). 
SSAs have also demonstrated to have an anti-neoplastic 
effect (Wolin 2012), but no data are still available about 
their effectiveness in malignant and/or metastatic 
gastrinoma in MEN1. The use of surgery is controversial 
due to the multiple microadenomatose nature of these 
tumors that are usually microscopic and scattered 
over the entire neuroendocrine tissue. Surgical tumor 
resection is suggested, by the consensus of experts, when 
the concomitant non-functioning NETs double their size 
in a 6 month-interval, or approach or overcome 2 cm in 
diameter (Thakker et al. 2012, Falconi et al. 2016). Several 
surgical options have been proposed, varying from 
the Thompson’s procedure (excision of the duodenal 
Tumor type Imaging technique Advantages Limitations
Insulinoma MRI  – It is the imaging of choice for localization of 
insulinoma
 – Non-delivering ionizing radiations; possibility 
of frequent serial imaging assessments
 – High sensitivity to detect insulinomas <1 cm 
(down to 0.5 cm)
 – It is not usually for diagnosis but for 
the assessment of primary localization 
and extent of the disease after the 
biochemical diagnosis is established
 – Long examination time
 – High cost
 CT  – Usually used as additional imaging modality 
for the correct pre-operative tumor 
localization, for evidencing the relationship 
to the pancreatic duct and assessment of 
metastatic disease
 – Exposure to ionizing radiations
 EUS  – Usually used as additional imaging 
modality for the correct pre-operative 
tumor localization and for evidencing the 
relationship to the pancreatic duct
 – Invasive technique, the procedure 
requires use of conscious sedation
 – Operator-dependent
 – Low sensitivity for distal pancreas
Non-
functioning 
pNETs
MRI  – Reduced radiation exposure
 – Similar sensitivity of CT scan
 – Non-invasive procedure
 – May miss pNETs less than 1.5–2 cm
 – Long examination time
 – High cost
 CT scan  – Possibility of a cross-sectional imaging analysis  – Exposure to ionizing radiations
 EUS  – High sensitivity to detect pancreatic tumors 
<1 cm (down to 0.5 cm)
 – Better indicated as pre-operative localization 
of tumors of an already identified tumor
 – It is the most sensitive technique to detect 
intra-pancreatic pNETs, both for functioning 
and non-functioning tumors
 – It allows accurate assessment of pNET size (can 
be used to monitor changes in pNET size)
 – Low sensitivity to detect tumor on the 
tail region of the pancreas
 – Invasive procedure, the procedure 
requires use of conscious sedation
 – Operator-dependent
 SRS with In-DPTA-
octreotide 
(octreoscan)
 – High sensitivity (overall 78%). More sensitive 
than cross-sectional imaging (MRI, CT) 
 – The advantage of allowing whole-body 
imaging at one time
 – Detection of distant metastases (bone, distant 
lymph nodes, soft tissues)
 – Miss 35–50% of pNETs less than 1 cm
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 – Greater sensitivity (92–94%) (down to 2–5 mm)
 – Excellent specificity (85%)
 – The advantage of allowing whole-body 
imaging at one time
 – Shorter imaging time
 – Lower radiation exposure
 – Cheaper cost
 – Gives a panoramic view of MEN1-related 
lesions (not only pNETs) at one assessment 
with a good sensitivity/specificity (including 
pituitary adenomas (75/83%) and adrenal 
adenomas (75/83%))
 – Beneficial for imaging of pNET metastases 
(liver and bone, distant lymph nodes, soft 
tissues)
 – Exposure to ionizing radiations
 – Vantages and positive data on its 
application is mostly derived from 
sporadic pNETs
 – A recent study on 33 MEN1 patients 
reported a low lesion detection rate for 
small tumors (<1 cm) (Albers et al. 2017)
 – The high physiological uptake of 
radiolabeled DOTATATE by the 
posterior portion of the pancreatic 
head can mask the real tumor uptake 
and can be responsible for the low 
detection rate of primary tumors in this 
region of the pancreas
CT, Computed tomography; EUS, Endoscopic ultrasounds; 68Ga-DOTATATE-PET/CT, 68Ga-DOTATATE positron-emission tomographic/CT imaging; MRI, 
Magnetic resonance imaging; pNETs, pancreatic neuroendocrine tumors; SRS, Somatostatin receptor scintigraphy.
Table 2 Continued.
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gastrinoma through a longitudinal duodenotomy) 
to duodeno-pancreatecomy or pancreas-preserving 
duodenectomy. At the moment, there are no controlled 
trials comparing the efficacy of medical treatment with 
respect to surgical options.
Insulinoma is the second most common functioning 
GEP-NET in MEN1, developing at young age (<35 years) 
in approximately 10–30% of cases. Insulinomas in MEN1 
can manifest as single pancreatic macroadenoma (>2 cm) 
or, more commonly, as multiple microadenomas (<2 cm) 
scattered along the entire pancreas. Diagnosis is made by 
concomitant fasting hypoglycemia and hyperinsulinemia. 
Tumors are generally localized by CT scan, MRI or EUS of 
pancreas body and tail. MRI is the imaging of choice for 
periodical surveillance; CT scan and EUS are usually used as 
additional imaging modalities for the correct pre-operative 
tumor localization and for evidencing the relationship 
to the pancreatic duct. Main characteristics of imaging 
tools for the detection and localization of insulinomas 
and other MEN1 GEP-NETs are summarized in Table  2. 
In the great majority of cases, pharmaceutical therapy 
fails to control hormone over-production and tumor 
surgery removal is mandatory to prevent neurological 
consequences of severe hypoglycemia. Differently from 
sporadic counterpart, MEN1 insulinoma is rarely treated 
by pancreatic enucleation due to the difficulty in localize 
the tumor in the contest of the multiple pNETs, both at 
pre- or intra-operatory level. Pancreatic enucleation can be 
proposed only in presence of few pNETs or of a dominant 
lesion responsible of the hypoglemic-hypersinulinemic 
syndrome. This procedure allows to preserve pancreatic 
parenchyma, and avoid pancreatic endocrine and 
exocrine insufficiency, but it presents the risk of Wirsung 
duct damage, pancreatic fistula (40% of cases), recurrence 
and inadequacy for malignant pNETs (Vezzosi et al. 2015). 
The most effective approach is pancreatic resection of the 
most affected part of the pancreas: either by distal corporo-
caudal-pancreatectomy (DP) or pancreato-duodenectomy 
(PD). Patients submitted to pancreatectomy are at 
risk to develop impaired glucose intolerance or overt 
diabetes mellitus (a risk significantly higher for PD or 
DP than for enucleation), risk that increases with the 
resected pancreas volume (>25%), the time elapsed from 
surgery and the age of patient (Kang et al. 2016). Splenic 
preservation, following DP, must be considered whenever 
there is no tumor infiltration of splenic vessels, since it 
is associated with a reduction in perioperative infectious 
complications compared with conventional DP with 
splenectomy (Shoup et al. 2002). PD should be preferably 
performed with a pylorus preserving technique instead of 
pylorus-antral resection (Whipple procedure) as suggested 
by some perioperative outcome measures (Huttner et al. 
2016), even if QoL does not seem to be different between 
the two procedures. Recently, a cross-sectional survey of 
recurrence-free survivors of a large number of patients who 
had undergone pancreatic resection has been published 
(Cloyd et al. 2017); a third of patients had a pNET. Patients 
who underwent a prior pancreatectomy for pNET had a 
significantly worse QoL scores with respect to patients 
operated for pancreatic or periampullary carcinomas. 
The type of surgery also influenced the post-surgical QoL: 
worse for DP than for PD. However, data about post-
surgical clinical complications and patient’s QoL have not 
been specifically evaluated in MEN1 insulinoma, yet.
NFTs of the gastro-entero-pancreatic tract occur 
prevalently as microadenomas and they are not associated 
with hormonal syndromes. Although these tumors are 
non-functional (not secreting any hormone or releasing 
neuroendocrine polypeptides that are not responsible for 
specific syndrome), it is very important to identify them early 
as their size usually correlates with metastases (4% if <1.0 cm, 
10% if between 1.1 and 2.0 cm, 18% if between 2.1 and 
3.0 cm, and 43% if >3.0), and malignant pNET is the most 
common cause of death. Growing sensitivity and specificity 
of imaging techniques have resulted in an increased 
identification of NFTs in MEN1 in the last decades. A 
combination of MRI, CT scan and EUS of the abdomen is 
suggested every year. Surgery is indicated to prevent tumor 
growth and malignant progression and to reduce morbidity 
and mortality related to metastatic disease. At the moment, 
no specific surgery consensus is defined about what tumor 
size can drive the decision for the intervention. Commonly, 
surgery is suggested for tumors over 2 cm and/or rapidly 
growing, but, recently, some authors have suggested to 
perform serial abdominal EUS in patients with small pNETs 
(<1–2 cm) and operate if growth occurs, others prefer 
avoiding surgery if non-functioning pNETs are less than 2 cm 
and/or slowly growing. Biopsy could help in identifying which 
patients will benefits from surgery. Unfortunately, studies on 
application of both the Ki-67 proliferation index and the 
TNM tumor staging index in non-functioning pNETs are on 
patients with sporadic pNETs and require specific evaluation 
in MEN1 tumors. In case of unresectable tumors (i.e. tumors 
spread all over the entire pancreas) or advanced metastatic 
cancer some medical therapies, such as SSAs, cytotoxic 
chemotherapy (streptozocin and 5-fluorouracil, doxorubicin, 
temozolomide with capecitabine), inhibitors of thyrosin 
kinase receptors (sunitinib), inhibitors of mammalian target 
of rapamycin (mTOR; everolimus) demonstrated to increase 
the median progression-free survival in sporadic pNETs. No 
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specific trials have been performed in MEN1 GEP-NETs, but 
there is reasonable assumption they would be effective also 
in these tumors.
Thymic, bronchopulmonary and 
gastric carcinoids
In MEN1, carcinoids of the thymus have a prevalence of 
28.2%, occurring predominantly in men than in women 
(20:1), with a significantly higher percentage in smokers. 
Thymic carcinoids represents the second cause of death in 
MEN1 patients after pNETs; mean year survival after the 
diagnosis is approximately 9.5 years (with 70% a patients 
dying as direct consequence of these tumors), and a 
10-year survival is limited only to 36.1% of diagnosed 
cases. Indeed, they are generally asymptomatic and do 
not display any clinical manifestation and, unfortunately, 
the great majority of them are discovered only at their 
advanced and malignant stage, when they have already 
invaded adjacent tissues, often also with liver and/or 
bone metastases. Therefore, the early identification of 
these tumors when they are still completely surgically 
resectable is mandatory. Diagnosis is exclusively by 
imaging, prevalently neck and chest low-dose contrast CT 
scan, or MRI, to be repeated every 12  years. CT scan is 
more sensitive (about 95%) but it implicates the exposure 
to repeated doses of ionizing radiation. Therefore, it 
has been proposed a screening combination of CT and 
interim MRI, each one to be, alternatively, repeated every 
two years (Table  1) to grant the annual exploration of 
neck-chest. Preventive total thymectomy is suggested at 
the time of parathyroid surgery, especially in men. Since 
transcervical thymectomy could not remove all thymic 
tissue, a combined transcervical thymectomy and a video-
assisted mediastinoscopic thymectomy, performed by an 
expert endocrinology surgeon, is indicated in high risk 
patients (smoker men).
Bronchopulmonary carcinoids occur in a low 
percentage of MEN1 patients (3.413.3% based on analyzed 
series). Diagnostic protocol consists of CT or MRI every 
12 years for the detection of possible bronchial masses. 
Surgery is the therapy of choice: lobectomy with lymph 
node dissection; most bronchopulmonary carcinoids 
can be completely resected. Survival rates do not differ 
between operated and non-operated patients. No clear 
indication about timing of surgery exists.
Type 2 gastric carcinoids derive from enterochromaffin-
like (ECL) cells (ECLomas), maybe as secondary to the 
thropic action of chronic hypergastrinemia and somatic 
11q13 LOH of these cells. In MEN1, these tumors are 
associated with ZES and peptic ulcers and present a high 
rate of liver metastases (1030%) (Norton et  al. 2015b). 
Early diagnosis is made by annual regular EUS of the 
stomach in MEN1 patients and MEN1 carriers. Localized 
single tumors (usually >7090% of cases) are surgically 
removed by endoscopic guidance. When tumors are 
numerous and large in size, pharmacological additional 
treatments, with cholecystokinin B receptor antagonists 
or long-acting SSAs, can be necessary, in association with 
aggressive surgery (subtotal or total stomach resection 
and D-2 lymph node dissection).
Conclusions
Main recommendations and suggestions for the best 
clinical and therapeutic management of MEN1, to reduce 
morbidity and mortality and grant a better QoL to patients 
and their relatives, can be resumed as it follows:
(1) MEN1 syndrome is a complex disorders involving 
different endocrine tissues and organs, and 
including also related hormone syndromes. Patients 
and their families should be clinically managed and 
life-long followed up by a multidisciplinary team of 
specialists able to treat all the different aspects of 
the disease, or by a specialist center in the area of 
endocrine tumors and related genetic bases, which 
includes and/or is in closed collaboration with 
endocrinologists, oncologists, gastroenterologists, 
specialized genetic counselors and clinical genetists, 
endocrine surgeons, histopathologists with 
expertise in NETs, radiologists with experience 
also in nuclear medicine, and biologists skilled 
in molecular genetics and genetic tests (Thakker 
et  al. 2012). MEN1 patients should be controlled 
regularly every 36 months; asymptomatic mutation 
carriers have to be appropriately reviewed every 
year. Follow-up by a specialist center demonstrated 
a significant reduction in morbidity and mortality, 
not only because of the choice of the best diagnostic 
and therapeutic plan but also because patients and 
relatives followed up in a specialist center show a 
higher adherence to both the diagnostic program 
and recommended therapies.
(2) General clinicians should refer index cases, suspected 
MEN1 patients and any suspicious and atypical case 
of MEN1, to specialist referral centers, for genetic 
counseling, genetic testing, targeted clinical and 
therapeutic management and follow-up.
(3) Unfortunately, in MEN1, preventive surgical ablation 
of target organs, to prevent the development of 
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tumors and their possible malignant progression, 
cannot be performed (as for thyroid in MEN2), except 
for thymus resection at the time of parathyroid 
surgery. Therefore, the early diagnosis is mandatory 
to start the specific diagnostic surveillance as soon 
as possible, and to precociously intervene by surgery 
and/or available pharmacological treatments to 
reduce negative effects of hormone over-secretion 
and related syndromes and to prevent malignant 
progression of tumors.
(4) Genetic testing is fundamental in MEN1 probands 
to confirm clinical diagnosis and to identify the 
specific MEN1 mutation, and in all first-degree 
relatives (better before the age of 5, or as soon as 
possible) for the early identification of asymptomatic 
mutation carriers. Positive tested individuals should 
undergo the MEN1 diagnostic protocol immediately 
at the time of mutation identification, as some MEN1 
tumors have been described by the age of 5.
(5) Genetic counseling should be performed before and 
after the genetic test and it should include: (i) the 
presence of personnel specialized in medical genetics, 
(ii) reproductive counseling, (iii) psychological 
support, for the management of genetic test result-
associate consequences involving the emotional, 
social, or financial aspect of life of patients and 
their families.
(6) Patients and their families should be given by accurate 
and clear information about: (i) the inheritance pattern 
of their disorders and the probability of inherit and/
or transmit the disease to the progeny, (ii) the genetic 
tests that will be performed and any potential error 
and limitation of every analysis technique, (iii) the 
risk for specific tumor development, their early age 
of onset, multiplicity and aggressiveness, associated 
with the result of the genetic test, (iv) all the clinical 
benefits derived from the result of genetic test, (v) all 
the available therapeutic options, and their benefits 
and possible risks.
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